Eczema Investigational Treatments
Filters
Age
Severity
Side Effects
Age
Eczema Severity Level
Max Side Effects Tolerated
Treatment
Who is this for?
Delivery
Effectiveness
Side Effects
Estimated Cost
-
LOWEST SIDE EFFECTSAmlitelimab(Amlitelimab)If you are over 12 years old and can't use topical steroids and are open to using an investigational medicineIf you can't use topical steroids and are open to using an investigational medicineInjection every 4 weeksLow
Side Effect Affected Nasopharyngitis 12% Upper respiratory tract infection 8% KEY TAKEAWAYS -
LOWEST SIDE EFFECTSAmlitelimab (Amlitelimab)Who is this for?:If you can't use topical steroids and are open to using an investigational medicineIf you are over 12 years old and can't use topical steroids and are open to using an investigational medicineEffectiveness:Side Effects:LowCost:Delivery:Injection every 4 weeksSee EvidenceDiscuss with a DermatologistKEY TAKEAWAYS
-
HIGHEST EFFICACY IN CATEGORYRocatinlimab(Rocatinlimab)If you are willing to use a new drug that's still being evaluatedIf you are willing to use a new drug that's still being evaluatedInjection Every 4-8 weeksMedium
Side Effect Affected pyrexia 17% nasopharyngitis 14% chills 11% headache 9% KEY TAKEAWAYSRocatinlimab significantly improves eczema symptoms compared to placebo. In clinical trials, patients receiving rocatinlimab saw 48-61% reduction in their eczema severity scores after 16 weeks, while those on placebo only saw 15% improvement.Study Summary Study Type Studied Population Results šRocatinlimab showed significant improvement in eczema symptoms compared to placebo after 16 weeks of treatment. The improvement was seen across all dosing groups, with reductions in disease severity ranging from 48% to 61%, compared to only 15% improvement with placebo.Clinical Trial Total Patients: 274šRocatinlimab is a new medication that blocks a specific receptor (OX40) on immune cells that contribute to eczema. The study showed that it significantly improved eczema symptoms in patients with moderate-to-severe disease. The medication was generally well-tolerated, with fever, common cold symptoms, and chills being the most common side effects.Clinical Trial Severity: moderate to severeAge: not availableThe medication shows particularly good results in treating eczema on the head and neck area, which is typically difficult to treat. The improvements in these areas lasted even after stopping treatment, with 77-100% of patients maintaining their improvement 20 weeks after discontinuing the medication.Study Summary Study Type Studied Population Results šRocatinlimab showed significant improvement in eczema symptoms across different body areas, particularly in the hard-to-treat head and neck region. The improvements lasted even after stopping treatment, with less than 25% of patients experiencing a return of symptoms in the head and neck area 20 weeks after discontinuation.Clinical Trial Total Patients: 219Severity: moderate to severeAge: 18+The most common side effects are fever (17% of patients), common cold symptoms (14%), chills (11%), headache (9%), mouth ulcers (7%), and nausea (6%). These side effects were generally mild and manageable.Study Summary Study Type Studied Population Results šRocatinlimab showed significant improvement in eczema symptoms compared to placebo after 16 weeks of treatment. The improvement was seen across all dosing groups, with reductions in disease severity ranging from 48% to 61%, compared to only 15% improvement with placebo.Clinical Trial Total Patients: 274šRocatinlimab is a new medication that blocks a specific receptor (OX40) on immune cells that contribute to eczema. The study showed that it significantly improved eczema symptoms in patients with moderate-to-severe disease. The medication was generally well-tolerated, with fever, common cold symptoms, and chills being the most common side effects.Clinical Trial Severity: moderate to severeAge: not availableUnlike some other eczema treatments, rocatinlimab works by targeting a specific immune system receptor called OX40, which helps control inflammatory T-cells. This unique mechanism may explain why improvements continue even after stopping treatment.Study Summary Study Type Studied Population Results šTwo new medications (rocatinlimab and amlitelimab) that work by blocking OX40-OX40L showed promising results in treating moderate-to-severe atopic dermatitis. Both medications showed significant improvement in eczema symptoms, with benefits lasting several weeks after stopping treatment.Review Severity: moderate to severeAge: not availableBoth medications showed significant improvement in eczema severity compared to placebo, with effects lasting after treatment discontinuation šRocatinlimab and amlitelimab are two new medications that work by targeting specific parts of the immune system (OX40-OX40L pathway) in atopic dermatitis. Both medications showed good results in clearing skin and reducing symptoms in patients with moderate-to-severe eczema, with acceptable safety.Review Severity: moderate to severeAge: not availableBoth medications showed better results than placebo in improving skin clearance and reducing symptoms -
HIGHEST EFFICACY IN CATEGORYRocatinlimab (Rocatinlimab)Who is this for?:If you are willing to use a new drug that's still being evaluatedIf you are willing to use a new drug that's still being evaluatedEffectiveness:Side Effects:MediumCost:Delivery:Injection Every 4-8 weeksSee EvidenceDiscuss with a DermatologistKEY TAKEAWAYS
Rocatinlimab significantly improves eczema symptoms compared to placebo. In clinical trials, patients receiving rocatinlimab saw 48-61% reduction in their eczema severity scores after 16 weeks, while those on placebo only saw 15% improvement.
Summary:Rocatinlimab showed significant improvement in eczema symptoms compared to placebo after 16 weeks of treatment. The improvement was seen across all dosing groups, with reductions in disease severity ranging from 48% to 61%, compared to only 15% improvement with placebo.Study Type:Clinical TrialStudied Population:Total Patients: 274Results:
Summary:Rocatinlimab is a new medication that blocks a specific receptor (OX40) on immune cells that contribute to eczema. The study showed that it significantly improved eczema symptoms in patients with moderate-to-severe disease. The medication was generally well-tolerated, with fever, common cold symptoms, and chills being the most common side effects.Study Type:Clinical TrialStudied Population:Severity: moderate to severeAge: not availableResults:
The medication shows particularly good results in treating eczema on the head and neck area, which is typically difficult to treat. The improvements in these areas lasted even after stopping treatment, with 77-100% of patients maintaining their improvement 20 weeks after discontinuing the medication.
Summary:Rocatinlimab showed significant improvement in eczema symptoms across different body areas, particularly in the hard-to-treat head and neck region. The improvements lasted even after stopping treatment, with less than 25% of patients experiencing a return of symptoms in the head and neck area 20 weeks after discontinuation.Study Type:Clinical TrialStudied Population:Total Patients: 219Severity: moderate to severeAge: 18+Results:
The most common side effects are fever (17% of patients), common cold symptoms (14%), chills (11%), headache (9%), mouth ulcers (7%), and nausea (6%). These side effects were generally mild and manageable.
Summary:Rocatinlimab showed significant improvement in eczema symptoms compared to placebo after 16 weeks of treatment. The improvement was seen across all dosing groups, with reductions in disease severity ranging from 48% to 61%, compared to only 15% improvement with placebo.Study Type:Clinical TrialStudied Population:Total Patients: 274Results:
Summary:Rocatinlimab is a new medication that blocks a specific receptor (OX40) on immune cells that contribute to eczema. The study showed that it significantly improved eczema symptoms in patients with moderate-to-severe disease. The medication was generally well-tolerated, with fever, common cold symptoms, and chills being the most common side effects.Study Type:Clinical TrialStudied Population:Severity: moderate to severeAge: not availableResults:
Unlike some other eczema treatments, rocatinlimab works by targeting a specific immune system receptor called OX40, which helps control inflammatory T-cells. This unique mechanism may explain why improvements continue even after stopping treatment.
Summary:Two new medications (rocatinlimab and amlitelimab) that work by blocking OX40-OX40L showed promising results in treating moderate-to-severe atopic dermatitis. Both medications showed significant improvement in eczema symptoms, with benefits lasting several weeks after stopping treatment.Study Type:ReviewStudied Population:Severity: moderate to severeAge: not availableResults:Both medications showed significant improvement in eczema severity compared to placebo, with effects lasting after treatment discontinuation
Summary:Rocatinlimab and amlitelimab are two new medications that work by targeting specific parts of the immune system (OX40-OX40L pathway) in atopic dermatitis. Both medications showed good results in clearing skin and reducing symptoms in patients with moderate-to-severe eczema, with acceptable safety.Study Type:ReviewStudied Population:Severity: moderate to severeAge: not availableResults:Both medications showed better results than placebo in improving skin clearance and reducing symptoms
-
Anzupgo(Delgocitinib)If your eczema is on your hands and topical steroids don't work for youIf your eczema is on your hands and topical steroids don't work for youTopical dailyMedium
Side Effect Affected Nasopharyngitis Contact dermatitis KEY TAKEAWAYSDelgocitinib ointment is effective at reducing eczema symptoms in both adults and children. In clinical trials, it significantly improved skin condition and reduced disease severity scores compared to placebo within 4 weeks of treatment.Study Summary Study Type Studied Population Results šDelgocitinib 0.5% ointment, a new topical treatment for eczema, reduced disease severity by 44.3% after 4 weeks of treatment, while the placebo group showed almost no improvement (1.7%). The medication remained effective for up to 28 weeks and was well-tolerated with mostly mild side effects.Clinical Trial Severity: moderate to severeAge: 16+Delgocitinib significantly improved eczema severity compared to vehicle šDelgocitinib ointment was tested in Japanese children with eczema and found to reduce disease severity by about 39% after 4 weeks of treatment, while those using a placebo ointment got worse. The medication remained effective for up to 56 weeks and was generally safe to use.Randomized Controlled Trial Severity: moderateAge: 2-15 yearsDelgocitinib significantly improved eczema symptoms while patients on vehicle got worse šDelgocitinib ointment (0.25% and 0.5%) significantly improved eczema symptoms in children aged 2-15 years compared to vehicle (placebo) ointment after 4 weeks of treatment. Both concentrations were safe to use and well-tolerated.Clinical Trial Both concentrations of delgocitinib significantly reduced eczema severity compared to vehicle The medication is generally safe and well-tolerated for long-term use (up to 52 weeks in adults and 56 weeks in children). Most side effects were mild and not related to the medication. Common side effects included common cold symptoms and mild skin reactions.Study Summary Study Type Studied Population Results šDelgocitinib 0.5% ointment was found to be safe and effective for treating atopic dermatitis in Japanese adults when used for up to one year. The improvement in eczema symptoms was maintained throughout the treatment period, and most side effects were mild.Clinical Trial Total Patients: 506Severity: not availableAge: 16+šDelgocitinib ointment was tested in Japanese children with eczema and found to reduce disease severity by about 39% after 4 weeks of treatment, while those using a placebo ointment got worse. The medication remained effective for up to 56 weeks and was generally safe to use.Randomized Controlled Trial Severity: moderateAge: 2-15 yearsDelgocitinib significantly improved eczema symptoms while patients on vehicle got worse Delgocitinib starts working quickly to reduce itching, with improvements noticed as early as the first day of treatment.Study Summary Study Type Studied Population Results šA new ointment called JTE-052 was tested in Japanese adults with moderate-to-severe eczema. The ointment significantly improved skin symptoms and reduced itching as early as the first night of treatment. All tested strengths (0.25%, 0.5%, 1%, and 3%) worked better than the vehicle (placebo) ointment, with the 3% strength showing the best results.Clinical Trial Total Patients: 327Severity: moderate to severeAge: 18+All strengths of JTE-052 significantly reduced eczema severity compared to vehicle, with 3% being most effective The medication comes in two strengths (0.25% and 0.5%). For children with mild eczema, the 0.5% strength may work better than the 0.25% strength, while both strengths work similarly for moderate to severe cases.Study Summary Study Type Studied Population Results šDelgocitinib ointment at 0.5% concentration worked better than 0.25% concentration for children with mild eczema, with 71.4% of patients seeing clear or almost clear skin compared to 46.2%. The medication was safe to use for up to 56 weeks, even when combined with other eczema treatments.Randomized Controlled Trial Severity: mild to severeAge: pediatric (specific range not provided)0.5% concentration was more effective for mild cases, while both concentrations showed similar efficacy in moderate-severe cases -
Anzupgo (Delgocitinib)Who is this for?:If your eczema is on your hands and topical steroids don't work for youIf your eczema is on your hands and topical steroids don't work for youEffectiveness:Side Effects:MediumCost:Delivery:Topical dailySee EvidenceDiscuss with a DermatologistKEY TAKEAWAYS
Delgocitinib ointment is effective at reducing eczema symptoms in both adults and children. In clinical trials, it significantly improved skin condition and reduced disease severity scores compared to placebo within 4 weeks of treatment.
Summary:Delgocitinib 0.5% ointment, a new topical treatment for eczema, reduced disease severity by 44.3% after 4 weeks of treatment, while the placebo group showed almost no improvement (1.7%). The medication remained effective for up to 28 weeks and was well-tolerated with mostly mild side effects.Study Type:Clinical TrialStudied Population:Severity: moderate to severeAge: 16+Results:Delgocitinib significantly improved eczema severity compared to vehicle
Summary:Delgocitinib ointment was tested in Japanese children with eczema and found to reduce disease severity by about 39% after 4 weeks of treatment, while those using a placebo ointment got worse. The medication remained effective for up to 56 weeks and was generally safe to use.Study Type:Randomized Controlled TrialStudied Population:Severity: moderateAge: 2-15 yearsResults:Delgocitinib significantly improved eczema symptoms while patients on vehicle got worse
Summary:Delgocitinib ointment (0.25% and 0.5%) significantly improved eczema symptoms in children aged 2-15 years compared to vehicle (placebo) ointment after 4 weeks of treatment. Both concentrations were safe to use and well-tolerated.Study Type:Clinical TrialStudied Population:Results:Both concentrations of delgocitinib significantly reduced eczema severity compared to vehicle
The medication is generally safe and well-tolerated for long-term use (up to 52 weeks in adults and 56 weeks in children). Most side effects were mild and not related to the medication. Common side effects included common cold symptoms and mild skin reactions.
Summary:Delgocitinib 0.5% ointment was found to be safe and effective for treating atopic dermatitis in Japanese adults when used for up to one year. The improvement in eczema symptoms was maintained throughout the treatment period, and most side effects were mild.Study Type:Clinical TrialStudied Population:Total Patients: 506Severity: not availableAge: 16+Results:
Summary:Delgocitinib ointment was tested in Japanese children with eczema and found to reduce disease severity by about 39% after 4 weeks of treatment, while those using a placebo ointment got worse. The medication remained effective for up to 56 weeks and was generally safe to use.Study Type:Randomized Controlled TrialStudied Population:Severity: moderateAge: 2-15 yearsResults:Delgocitinib significantly improved eczema symptoms while patients on vehicle got worse
Delgocitinib starts working quickly to reduce itching, with improvements noticed as early as the first day of treatment.
Summary:A new ointment called JTE-052 was tested in Japanese adults with moderate-to-severe eczema. The ointment significantly improved skin symptoms and reduced itching as early as the first night of treatment. All tested strengths (0.25%, 0.5%, 1%, and 3%) worked better than the vehicle (placebo) ointment, with the 3% strength showing the best results.Study Type:Clinical TrialStudied Population:Total Patients: 327Severity: moderate to severeAge: 18+Results:All strengths of JTE-052 significantly reduced eczema severity compared to vehicle, with 3% being most effective
The medication comes in two strengths (0.25% and 0.5%). For children with mild eczema, the 0.5% strength may work better than the 0.25% strength, while both strengths work similarly for moderate to severe cases.
Summary:Delgocitinib ointment at 0.5% concentration worked better than 0.25% concentration for children with mild eczema, with 71.4% of patients seeing clear or almost clear skin compared to 46.2%. The medication was safe to use for up to 56 weeks, even when combined with other eczema treatments.Study Type:Randomized Controlled TrialStudied Population:Severity: mild to severeAge: pediatric (specific range not provided)Results:0.5% concentration was more effective for mild cases, while both concentrations showed similar efficacy in moderate-severe cases
Other Investigational Treatments
Treatment
Who is this for?
Delivery
Effectiveness
Side Effects
Estimated Cost
Eczema is more than skin deep
Join our waitlist while we set up personalized holistic eczema care.
Choose Your Preferences to Optimize Your Treatment
Age
Eczema Severity Level
Max Side Effects Tolerated
Insurance Coverage
Include Steroidal Creams